254 related articles for article (PubMed ID: 37085531)
1. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder.
Hua DY; Hindocha C; Baio G; Lees R; Shaban N; Morgan CJ; Mofeez A; Curran HV; Freeman TP
Transl Psychiatry; 2023 Apr; 13(1):131. PubMed ID: 37085531
[TBL] [Abstract][Full Text] [Related]
2. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder.
Lees R; Hines LA; Hindocha C; Baio G; Shaban NDC; Stothart G; Mofeez A; Morgan CJA; Curran HV; Freeman TP
Psychopharmacology (Berl); 2023 Feb; 240(2):337-346. PubMed ID: 36598543
[TBL] [Abstract][Full Text] [Related]
3. Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study.
Chester LA; Englund A; Chesney E; Oliver D; Wilson J; Sovi S; Dickens AM; Oresic M; Linderman T; Hodsoll J; Minichino A; Strang J; Murray RM; Freeman TP; McGuire P
Cannabis Cannabinoid Res; 2024 Feb; 9(1):188-198. PubMed ID: 36493386
[No Abstract] [Full Text] [Related]
4. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.
Freeman TP; Hindocha C; Baio G; Shaban NDC; Thomas EM; Astbury D; Freeman AM; Lees R; Craft S; Morrison PD; Bloomfield MAP; O'Ryan D; Kinghorn J; Morgan CJA; Mofeez A; Curran HV
Lancet Psychiatry; 2020 Oct; 7(10):865-874. PubMed ID: 32735782
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
7. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
8. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS
JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917
[TBL] [Abstract][Full Text] [Related]
9. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
[TBL] [Abstract][Full Text] [Related]
10. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.
Lawn W; Trinci K; Mokrysz C; Borissova A; Ofori S; Petrilli K; Bloomfield M; Haniff ZR; Hall D; Fernandez-Vinson N; Wang S; Englund A; Chesney E; Wall MB; Freeman TP; Curran HV
Addiction; 2023 Jul; 118(7):1282-1294. PubMed ID: 36750134
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of cannabidiol trials in neurodevelopmental disorders.
Parrella NF; Hill AT; Enticott PG; Barhoun P; Bower IS; Ford TC
Pharmacol Biochem Behav; 2023 Sep; 230():173607. PubMed ID: 37543051
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of Δ
Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
[TBL] [Abstract][Full Text] [Related]
13. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.
Morgan CJA; Freeman TP; Hindocha C; Schafer G; Gardner C; Curran HV
Transl Psychiatry; 2018 Sep; 8(1):181. PubMed ID: 30185793
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
15. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.
Hutten NRPW; Arkell TR; Vinckenbosch F; Schepers J; Kevin RC; Theunissen EL; Kuypers KPC; McGregor IS; Ramaekers JG
Psychopharmacology (Berl); 2022 Nov; 239(11):3731-3741. PubMed ID: 36227352
[TBL] [Abstract][Full Text] [Related]
16. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
17. Individual and combined effects of cannabidiol and Δ
Wall MB; Freeman TP; Hindocha C; Demetriou L; Ertl N; Freeman AM; Jones AP; Lawn W; Pope R; Mokrysz C; Solomons D; Statton B; Walker HR; Yamamori Y; Yang Z; Yim JL; Nutt DJ; Howes OD; Curran HV; Bloomfield MA
J Psychopharmacol; 2022 Jun; 36(6):732-744. PubMed ID: 35596578
[TBL] [Abstract][Full Text] [Related]
18. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity.
Wall MB; Pope R; Freeman TP; Kowalczyk OS; Demetriou L; Mokrysz C; Hindocha C; Lawn W; Bloomfield MA; Freeman AM; Feilding A; Nutt D; Curran HV
J Psychopharmacol; 2019 Jul; 33(7):822-830. PubMed ID: 31013455
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?
Rømer Thomsen K; Thylstrup B; Kenyon EA; Lees R; Baandrup L; Feldstein Ewing SW; Freeman TP
Neurosci Biobehav Rev; 2022 Jan; 132():169-180. PubMed ID: 34822876
[TBL] [Abstract][Full Text] [Related]
20. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]